Calquence Tablets Dosage
Generic name: ACALABRUTINIB 100mg
Dosage form: tablet, film coated
Drug class: BTK inhibitors
Medically reviewed by Drugs.com. Last updated on Jun 5, 2024.
Recommended Dosage
CALQUENCE as Monotherapy
For patients with MCL, CLL, or SLL, the recommended dosage of CALQUENCE is 100 mg taken orally approximately every 12 hours until disease progression or unacceptable toxicity.
CALQUENCE in Combination with Obinutuzumab
For patients with previously untreated CLL or SLL, the recommended dosage of CALQUENCE is 100 mg taken orally approximately every 12 hours until disease progression or unacceptable toxicity. Start CALQUENCE at Cycle 1 (each cycle is 28 days). Start obinutuzumab at Cycle 2 for a total of 6 cycles and refer to the obinutuzumab prescribing information for recommended dosing. Administer CALQUENCE prior to obinutuzumab when given on the same day.
Advise patients to swallow tablet whole with water. Advise patients not to chew, crush, dissolve, or cut the tablets. CALQUENCE may be taken with or without food. If a dose of CALQUENCE is missed by more than 3 hours, it should be skipped and the next dose should be taken at its regularly scheduled time. Extra tablets of CALQUENCE should not be taken to make up for a missed dose.
Recommended Dosage for Drug Interactions
Dosage Modifications for Use with CYP3A Inhibitors or Inducers
These are described in Table 1.
CYP3A |
Co-administered Drug |
Recommended CALQUENCE use |
Inhibition |
Strong CYP3A inhibitor |
Avoid co-administration. If these inhibitors will be used short-term (such as anti‑infectives for up to seven days), interrupt CALQUENCE. After discontinuation of strong CYP3A inhibitor for at least 24 hours, resume previous dosage of CALQUENCE. |
Moderate CYP3A inhibitor |
Reduce the CALQUENCE 100 mg every 12 hours dosage to 100 mg once daily. |
|
Induction |
Strong CYP3A inducer |
Avoid co-administration. If co-administration is unavoidable, increase CALQUENCE dosage to 200 mg approximately every 12 hours. |
Dosage Modifications for Adverse Reactions
Recommended dosage modifications of CALQUENCE for Grade 3 or greater adverse reactions are provided in Table 2.
Event | Adverse Reaction Occurrence | Dosage Modification (Starting dose = 100 mg approximately every 12 hours) |
---|---|---|
Grade 3 or greater non-hematologic toxicities, Grade 3 thrombocytopenia with bleeding, Grade 4 thrombocytopenia or Grade 4 neutropenia lasting longer than 7 days |
First and Second |
Interrupt CALQUENCE. Once toxicity has resolved to Grade 1 or baseline level, CALQUENCE may be resumed at 100 mg approximately every 12 hours. |
Third |
Interrupt CALQUENCE. Once toxicity has resolved to Grade 1 or baseline level, CALQUENCE may be resumed at a reduced frequency of 100 mg once daily. |
|
Fourth |
Discontinue CALQUENCE. |
|
Adverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). |
Refer to the obinutuzumab prescribing information for management of obinutuzumab toxicities.
Frequently asked questions
More about Calquence (acalabrutinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (29)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: BTK inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.